跳至主要内容
临床试验/JPRN-UMIN000006442
JPRN-UMIN000006442已完成未知

Observational study of Serum HER2 in HER2 negative advanced gastric cancer treated with capecitabine plus cisplatin(XP) - SHERLOCK2 Trial

Sapporo Medical University 1st department of Internal Medicine0 个研究点目标入组 50 人开始时间: 2011年9月29日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1)Other malignancies within the last 2 years, except for carcinoma in situ or basal cell carcinoma. 2)Positive serum pregnancy test in women of childbearing, or lactating women. 3)History of psychiatric disability judged by investigator to be clinically significant, precluding informed consent. 4)Serious intercurrent infections. 5)Patients whom physician determines as inappropriate

研究者

发起方
Sapporo Medical University 1st department of Internal Medicine

相似试验